regorafenib + toripalimab + albumin paclitaxel

This is a combination therapy consisting of **regorafenib** (a multi-kinase inhibitor), **toripalimab** (a humanized monoclonal antibody against PD-1), and **albumin-bound paclitaxel** (nab-paclitaxel, a formulation of paclitaxel bound to albumin nanoparticles). The combination is in clinical investigation as a third-line treatment for unresectable or metastatic pancreatic cancer. - **Regorafenib** inhibits multiple receptor tyrosine kinases involved in tumor angiogenesis (such as VEGFR), oncogenesis, and the tumor microenvironment. - **Toripalimab** targets and blocks the PD-1 immune checkpoint on T cells, enhancing the immune response against tumors. - **Albumin-bound paclitaxel** disrupts microtubule function, inhibiting cancer cell division, with its albumin-bound formulation improving delivery and reducing toxicity compared to conventional formulations. This combination is being studied for its potential to improve efficacy by leveraging complementary mechanisms: enhancing immune-mediated antitumor activity, blocking angiogenesis, and directly cytotoxic effects on tumor cells[1][2][3][7][10].

Other names

regorafenib combined with toripalimab and albumin paclitaxelregorafenib + toripalimab + nab-paclitaxel